4DMedical Ltd ( (AU:4DX) ) has provided an announcement.
4DMedical Limited has announced an Extraordinary General Meeting scheduled for May 1, 2025, in Melbourne, Australia. The meeting will address several business matters, including the ratification of shares issued under a placement and the approval of new options. This meeting is significant for stakeholders as it involves key decisions impacting the company’s financial strategies and shareholder interests.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in respiratory imaging technology. The company utilizes advanced imaging and AI-powered solutions to provide insights into lung function, facilitating earlier and more precise diagnoses of respiratory diseases. Their patented XV Technology® and FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) are key innovations that enhance diagnostic capabilities. 4DMedical’s solutions are integrated into hospital infrastructure through a Software as a Service (SaaS) model. The company expanded its capabilities with the acquisition of Imbio, an AI solutions provider for lung and cardiothoracic diseases.
YTD Price Performance: -39.58%
Average Trading Volume: 1,005,146
Technical Sentiment Signal: Buy
Current Market Cap: A$130.6M
See more data about 4DX stock on TipRanks’ Stock Analysis page.